MorphoSys (Group)

http://www.morphosys.com

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 320 employees. *

	Start	1992-01-01 established
	Today	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Predecessor	Max Planck Society for the Advancement of Science
	Industry	biopharmaceutical
	Person	Moroney, Simon E. (MorphoSys 1992– CEO + Founder)
	Person 2	Holstein, Jens (MorphoSys 201105– CFO before Regional CFO Fresenius Kabi + Managing Director Fresenius Kabi Deutschland)

	Region	Martinsried
	Country	Germany
	Street	7 Semmelweisstr.
	City	82152 Planegg
	Tel	+49-89-89927-0
		Address record changed: 2018-07-24

Basic data	Employees	D: 101 to 500 (2017-12-31)
	Currency	EUR
	Annual sales	76,442,505 (revenues, consolidated (2018) 2018-12-31)
	Profit	-56,172,121 (2018-12-31)
	Cash	45,459,836 (2018-12-31)

		* Document for ï¿½About Sectionï¿½: MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg.

		Record changed: 2019-03-16